Risk Stratification for Late-Onset CMV Infection Following Prophylaxis With Letermovir in Allogeneic Stem Cell Transplant Recipients: Unraveling the Potential Role of CMV-Specific Cell-Mediated Immunity.

Prevymis (letermovir) - Merck (MSD)

http://www.ncbi.nlm.nih.gov/pubmed/42270439

Alessandro Busca; Carolina Secreto; Chiara Dellacasa; Cristina Costa; Francesca Bassi; Francesca Sidoti; Francesco Giuseppe De Rosa; Lorenzo Celona; Luca Legato; Luisa Giaccone; Roberto Passera; Sara Muccio; Silvia Corcione; Sofia Zompi

Jun 11, 2026